Description: <p><b>Kaempferol</b> — a naturally occurring dietary flavonol polyphenol (3,4′,5,7-tetrahydroxyflavone) found in vegetables, fruits, tea, legumes, and medicinal plants, where it commonly occurs as glycosides rather than free aglycone. It is classified as a bioactive dietary flavonoid/flavonol and experimental natural-product therapeutic; common abbreviations include KMP, KPF, KF, and KAE. Major food sources include kale and other leafy vegetables, tea, broccoli, beans, onions, capers, and some fruits. Kaempferol is a multi-target compound with substantial preclinical anticancer and neuroprotective evidence, but it is not an approved anticancer or Alzheimer’s disease drug.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>PI3K/AKT/mTOR inhibition → suppression of proliferation and survival signaling, with induction of apoptosis and autophagy.</li>
<li>Mitochondrial and death-receptor apoptosis → ↑ Bax/Bad/Bik, ↓ Bcl-2/Bcl-xL, ↑ mitochondrial permeability and cytochrome-c release, and activation of caspase-8/9/3 pathways.</li>
<li>Cell-cycle suppression → G0/G1 or G2/M arrest depending on tumor model, with altered cyclins/CDKs and frequent participation of p53 signaling.</li>
<li>MAPK and STAT signaling modulation → generally ↓ proliferative ERK/STAT3 signaling, while JNK/p38 effects are strongly model- and dose-dependent.</li>
<li>NF-κB and inflammatory signaling suppression → ↓ pro-survival and inflammatory transcription, including context-dependent reductions in COX-2 and inflammatory mediators.</li>
<li>ROS/redox modulation → frequently ↑ oxidative/mitochondrial stress in cancer cells at cytotoxic concentrations, while lower exposures in normal tissues commonly produce antioxidant and NRF2-dependent cytoprotection.</li>
<li>Migration, EMT, invasion and angiogenesis inhibition → ↓ EGFR/Src/FAK signaling, MMP activity, HIF-1α/VEGF signaling and other metastatic programs in selected models.</li>
<li>Metabolic suppression → inhibition of glycolysis, including PKM2-linked glycolytic metabolism in some tumor models, which can contribute to reversal of chemotherapy resistance.</li>
<li>Ferroptosis modulation → emerging evidence indicates that kaempferol can promote ferroptotic tumor-cell death in selected cancers, while conversely suppressing pathological ferroptosis in non-cancer tissues; direction is therefore highly context-dependent.</li>
<li>Epigenetic modulation → direct broad HDAC inhibition has been demonstrated experimentally at micromolar concentrations and may contribute to altered transcription and growth suppression.</li>
<li>Therapy sensitization → increased responsiveness to radiation, cisplatin, TRAIL and other anticancer treatments has been demonstrated preclinically through PI3K/AKT, mitochondrial apoptosis, metabolic and drug-resistance mechanisms.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Oral kaempferol is absorbed but undergoes extensive intestinal and hepatic conjugation, particularly glucuronidation and sulfation, so circulating material is predominantly metabolites rather than free aglycone. In a human study using 9 mg dietary kaempferol, mean plasma Cmax was approximately 0.1 µM at about 5.8 hours, with kaempferol-3-glucuronide the major circulating form. Food matrix, glycoside structure, microbiota and formulation substantially influence exposure. Nanoformulations, lipid carriers and related delivery approaches are being investigated to improve systemic exposure but remain experimental for oncology.<br>
-research options to improve bioavailability include: take with oil (not water soluble), add Lecithin. Examples: extra virgin olive oil, nuts, egg yolk<br>
-consuming kaempferol from kale, broccoli, onions or similar foods, most of it is present as glycosides, so mostly dependent on gut microbiota (not oil, etc)
</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most direct anticancer studies use approximately 10–100 µM kaempferol; reported IC50 values are often around 20–60 µM depending on tumor type. These concentrations generally exceed the sub-µM systemic concentrations observed after ordinary dietary exposure. Consequently, many direct cytotoxic, HDAC-inhibitory, ROS-generating and ferroptotic effects should not be assumed to occur systemically after normal dietary intake. Local gastrointestinal exposure and specialized formulations may provide different exposure conditions.<br>
-Human dietary exposure generally produces circulating kaempferol concentrations in the nanomolar to low-submicromolar range; plasma Cmax of approximately 0.1 µM has been reported after a 9-mg dietary dose. Therefore, in-vitro exposures of 10–20 µM are roughly two orders of magnitude above concentrations demonstrated after ordinary dietary intake.</p>
<p><b>Clinical evidence status:</b> <b>Preclinical.</b> Anticancer evidence consists predominantly of cell-culture and animal studies, including xenograft studies and preclinical radiosensitization/chemosensitization. There is no established therapeutic oncology indication and no convincing cancer-treatment RCT evidence for kaempferol itself. Human evidence includes epidemiologic dietary associations, pharmacokinetic studies and a small randomized safety study in healthy adults; 50 mg/day kaempferol aglycone for four weeks was well tolerated in that study. Clinical efficacy for cancer remains unproven.</p>
<br>
<h3>Kaempferol Mechanistic Effects</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>PI3K AKT mTOR</td>
<td>↓ PI3K; ↓ AKT; ↓ mTOR</td>
<td>↔ / context-dependent</td>
<td>R–G</td>
<td>↓ survival and proliferation; ↑ apoptosis and autophagy</td>
<td>One of the most reproducible anticancer axes; direct PI3K inhibition has been demonstrated experimentally.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial and death receptor apoptosis</td>
<td>↑ Bax/Bad/Bik; ↓ Bcl-2/Bcl-xL; ↑ Cyt-c; ↑ caspase-8/9/3</td>
<td>↔ at lower exposure</td>
<td>R–G</td>
<td>↑ programmed cell death</td>
<td>Both intrinsic mitochondrial and extrinsic death-receptor pathways can participate.</td>
</tr>
<tr>
<td>3</td>
<td>Cell cycle and p53</td>
<td>↑ p53 (model-dependent); ↑ G0/G1 or G2/M arrest</td>
<td>↔</td>
<td>G</td>
<td>↓ proliferation</td>
<td>Exact checkpoint depends strongly on cancer type and exposure.</td>
</tr>
<tr>
<td>4</td>
<td>MAPK and STAT signaling</td>
<td>↓ ERK; ↓ STAT3; JNK/p38 ↔ (context-dependent)</td>
<td>↔ / protective MAPK modulation</td>
<td>R–G</td>
<td>↓ proliferative signaling; ↑ apoptosis</td>
<td>JNK and p38 direction is not uniform across models and should not be assigned a universal direction.</td>
</tr>
<tr>
<td>5</td>
<td>NF-κB inflammatory survival signaling</td>
<td>↓ NF-κB; ↓ p65; ↓ inflammatory and anti-apoptotic transcription</td>
<td>↓ pathological inflammation</td>
<td>R–G</td>
<td>Anti-inflammatory and anti-survival activity</td>
<td>Potentially relevant to both tumor cells and the tumor microenvironment.</td>
</tr>
<tr>
<td>6</td>
<td>Mitochondrial ROS and NRF2 redox response</td>
<td>↑ ROS (dose-dependent); NRF2 ↔ (context-dependent)</td>
<td>↓ ROS; ↑ NRF2 (context-dependent)</td>
<td>P–G</td>
<td>Tumor oxidative stress versus normal-cell cytoprotection</td>
<td>Biphasic redox behavior is important: pro-oxidant anticancer effects generally require substantially higher exposure than dietary systemic exposure.</td>
</tr>
<tr>
<td>7</td>
<td>EGFR EMT migration and angiogenesis</td>
<td>↓ EGFR/Src/ERK/AKT; ↓ FAK; ↓ MMPs; ↓ migration; ↓ VEGF</td>
<td>↔</td>
<td>G</td>
<td>↓ invasion, metastasis and angiogenesis</td>
<td>Evidence is predominantly preclinical and varies among tumor types.</td>
</tr>
<tr>
<td>8</td>
<td>Glycolytic metabolism</td>
<td>↓ PKM2; ↓ glycolysis; ↓ lactate production (model-dependent)</td>
<td>↔</td>
<td>R–G</td>
<td>↓ tumor bioenergetics and drug resistance</td>
<td>Particularly relevant to reported reversal of 5-FU resistance; not yet established as a universal kaempferol mechanism.</td>
</tr>
<tr>
<td>9</td>
<td>Ferroptosis</td>
<td>↑ ferroptosis (model-dependent)</td>
<td>↓ pathological ferroptosis (context-dependent)</td>
<td>R–G</td>
<td>Redox-dependent cell death modulation</td>
<td>Emerging cancer evidence includes CA9-associated ferroptosis in oral squamous cell carcinoma; direction reverses in some neuroprotective models.</td>
</tr>
<tr>
<td>10</td>
<td>HDAC epigenetic regulation</td>
<td>↓ HDAC activity; ↑ histone acetylation</td>
<td>↔; toxicity at high concentration</td>
<td>G</td>
<td>Epigenetic growth suppression</td>
<td>Pan-HDAC inhibition has been demonstrated in vitro; translational relevance is constrained by the micromolar exposure required.</td>
</tr>
<tr>
<td>11</td>
<td>Radio and chemosensitization</td>
<td>↑ radiation response; ↑ cisplatin/TRAIL response; ↓ resistance mechanisms</td>
<td>↔ / relative sparing in some models</td>
<td>G</td>
<td>Adjunct anticancer potential</td>
<td>Demonstrated in cell and animal experiments but not established clinically.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>Required cytotoxic concentrations commonly exceed systemic dietary exposure</td>
<td>Dietary and short-term supplemental exposures appear considerably better tolerated</td>
<td>G</td>
<td>PK and clinical-evidence limitation</td>
<td>Rapid conjugation, low free-aglycone exposure, heterogeneous mechanisms and absence of therapeutic oncology trials remain major barriers.</td>
</tr>
</table>
<p><b>TSF:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br><br>
<p><b>Alzheimer’s disease:</b> Kaempferol has substantial preclinical neuroprotective evidence in cellular and animal models of Alzheimer’s disease and sporadic dementia, but no established human therapeutic efficacy. Reported mechanisms include ↓ oxidative stress and neuroinflammation, ↓ Aβ-associated toxicity and deposition, ↓ neuronal apoptosis, modulation of AChE, improvement of synaptic/neurotrophic signaling, and suppression of pathological neuronal ferroptosis. Recent evidence implicates NRF2/HO-1/GPX4-associated antioxidant and ferroptosis-control pathways. Cognitive and memory improvements have been reported in several rodent models; these findings have not yet been validated in clinical AD trials.</p>
<h3>Kaempferol in Alzheimer’s Disease</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Oxidative stress and NRF2 defense</td>
<td>↓ ROS/lipid oxidation; ↑ NRF2/HO-1 antioxidant signaling</td>
<td>Neuronal protection</td>
<td>One of the most consistently reported mechanisms across preclinical AD models.</td>
</tr>
<tr>
<td>2</td>
<td>Aβ pathology</td>
<td>↓ Aβ toxicity/deposition</td>
<td>↓ amyloid-associated neuronal injury</td>
<td>Demonstrated in cellular and animal models; clinical relevance remains unknown.</td>
</tr>
<tr>
<td>3</td>
<td>Neuroinflammation</td>
<td>↓ inflammatory signaling</td>
<td>↓ neuronal inflammatory stress</td>
<td>Likely overlaps with NF-κB and oxidative-stress modulation.</td>
</tr>
<tr>
<td>4</td>
<td>Neuronal ferroptosis</td>
<td>↓ Fe²⁺; ↓ lipid ROS; ↑ GPX4/SLC7A11/AKR1C3-associated defense</td>
<td>↓ ferroptotic neuronal death</td>
<td>Emerging evidence; contrasts with pro-ferroptotic effects reported in certain cancer models.</td>
</tr>
<tr>
<td>5</td>
<td>Tau pathology</td>
<td>↓ phosphorylated Tau (model-dependent)</td>
<td>↓ neurodegenerative pathology</td>
<td>Recent animal evidence; replication and human validation are required.</td>
</tr>
<tr>
<td>6</td>
<td>Acetylcholinesterase</td>
<td>↓ AChE (preclinical)</td>
<td>Potential ↑ cholinergic signaling</td>
<td>Evidence is substantially weaker than for approved AChE inhibitors and should not imply comparable clinical efficacy.</td>
</tr>
<tr>
<td>7</td>
<td>Cognition and memory</td>
<td>↑ learning; ↑ memory performance</td>
<td>Functional neuroprotection</td>
<td>Observed in several rodent models; no established human AD efficacy.</td>
</tr>
</table>